Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group

Eva Kimby Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSwedenCorrespondence[email protected]

Jesper Jurlander Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden

Christian Geisler Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden

Hans Hagberg Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden

Harald Holte Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden

Tuula Lehtinen Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden

Björn Östenstad Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden

Mads Hansen Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden

Anders Österborg Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden

Ola Lindén Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden

Christer Sundström Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden

On Behalf Of The Nordic Lymphoma Group Karolinska University Hospital, Stockholm, Sweden, Rigshospitalet, Copenhagen, Denmark, Academic Hospital, Uppsala, Sweden, Rikshospitalet - Radiumhospitalet Medical Center, Oslo, Norway, University Hospital, Tampere, Finland, Ullevål hospital, Oslo, Norway and Lund University HospitalSweden

show all

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date